Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.


  1. Advanced Patent Search
Publication numberUS3867529 A
Publication typeGrant
Publication dateFeb 18, 1975
Filing dateApr 18, 1973
Priority dateAug 24, 1970
Publication numberUS 3867529 A, US 3867529A, US-A-3867529, US3867529 A, US3867529A
InventorsCesare Casagrande, Giorgio Ferrari
Original AssigneeCesare Casagrande, Giorgio Ferrari
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Tranquilizing and anti-anxiety pharmaceutical compositions
US 3867529 A
Tranquillizing and anti-anxiety pharmaceutical compositions are disclosed comprising, as the active ingredient, a 1,4-benzo-diazepine derivative containing a carbamic ester group, having the general formula:
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States Patent [191 Ferrari et al.

[ Feb.. 18, 1975 TRANQUILIZING AND ANTI-ANXIETY PHARMACEUTICAL COMPOSITIONS [76] Inventors: Giorgio Ferrari, Milan; Cesare Casagrande, Como, both of Italy 221 Filed: Apr. 18, 1973 [2i] Appl. No.: 352,105

Related US. Application Data [63] Continuation-impart of Ser. No. 173,305, Aug. 19,

1971, Pat. N0. 3,799,920.

[30] Foreign Application Priority Data Aug. 24, 1970 Switzerland 126620/70 424/267, 424/274 [51] Int. Cl A6lk 27/00 [58] Field of Search 424/248, 250, 267, 274

[56] References Cited UNITED STATES PATENTS 3,296.24) l/l967 Bell 260/2393 D Primary Examiner-Stanley J. Friedman Allorney, Agent, or Firm-B. Edward Shlesinger [57] ABSTRACT Tranquillizing and anti-anxiety pharmaceutical compositions are disclosed comprising, as the active ingredient, a 1,4-benzo-diazepine derivative containing a carbamic ester group, having the general formula:

The therapeutical method is also described.

13 Claims, 4 Drawing Figures SHEET 1 OF 4 (185.1 -aas.0)

' Una-41.5.0)

O O5 z D Compound Medazepam Temazepam Chlor- Diazepam 5 diaz e poxlde Effect of comp.N?6and.of some. other benzodiazepine compounds on the traction test in the mouse. 7 I

MD =doses vin mg./kg./os which cause the myorelaxing effect in the 90% of the mice.

PATENTEB 3,867,529

SHEET 2 [IF 4 o 01 Z O Comp. N6 Medazepam Temazepam Chlor- Diazepam dialepoxlde Effect of compound N96 and of some other benzodiazepine compounds in the rotarod test in the mouse.

MD =doSeS in mg./kg./os which cause the myorelaxing effect in the 90% the mice.

PAIEIIIEQ 3,867, 529 SHEET 3 OF 4 Effects on the left ventricular pressure (p'vs) and F" dp/dt in the awake dog. ,3

l variation of p vs Compound N96 (mg. 1/kg. iv) I- hlordiazepoxide (mg. 1/kg. iv)

I I I l i I o 1 3 5 1S tlme (m|ns.

% variation of E2 of pvs dl Compound N96 (mg. 1/kg iv) Chlordiazepoxide (mg;1/kg. iv)

I I I I I I 0 1 3 s 10 1s 30 time (mins) PATENIEDFEB i 8 W5 3 v 8 6 7, 52s

' SHEET u F 4 Effects on the left ventricular pressure (pvs) and f dp/dt in the awake dog. I

lo variation of p v s Compound N? 6 mg. kg. iv) 100 *IK- ry-=1: Chlordiazepoxide (mg; S/kg. iv)

II I I I I I l -O 1 3 5 D time; (m|ns.)

% variation of P of pvs Compound N. 6 (mg. S/kg. iv)

v Chlqrdiazepoxide (.mg. S/kg. iv)

l i l l v 0 1 3 5 1O 15 30 time (mins.)

1 TRANQUILIZING AND ANTI-ANXIETY PHARMACEUTICAL COMPOSITIONS This Application is a continuation-in-part of the U.S. application Ser. No. 173,305 filed Aug. 19, 1971, now U.S. Pat. No. 3,799,920.

This invention relates to pharmaceutical compositions containing, as the active ingredient, an 1,4- benzodiazepine derivative having the general formula:

wherein R is hydrogen, or a lower alkyl having l to 4 carbon atoms, and R and R are, each, hydrogen, a lower alkyl of l to 4 carbon atoms, a cycloalkyl or lower alkyl bearing as a substituent an amine or hydroxy group, and R and R;, can also form, conjointly, a polymethylene chain or also a polymethylene chain containing one heteroatom Since 1962 the class of the 1,4-benzodiazepine has been extensively investigated as to their possible application as psychopharmacological agents and several compounds of this class have achieved a widespread therapeutic use.

However some problems and disadvantages arose with respect to their long term therapeutical use, namely:

their toxicity is rather high, so that a great deal of care is needed as to their administration;

some objectionable side effects are induced by their use, namely exceedingly high sedative action and muscle relaxation liable to induce depression, drowsiness. fatigue and reduced working capability.

It has surprisingly been found that some compounds having the above formula (I), when used as the active ingredient of a tranquillizer and anti-anxiety drug, show considerably improved properties, and are both weakly toxic and devoid of objectionable side effects, thus permitting a more intense therapy without the asthenizing effect. characteristic of the prior art compounds.

These and other objects are achieved, according to the present invention, by means of a pharmaceutical composition, useful for tranquillizing and anti-anxiety use, as well as for the treatment of depressing moods, psychoneuroses and psychosomatic ailments, characterized in that the active ingredient is selected amongst the compounds of the formula (I) above referred to, said compound being present at a dosage of 5 to 30 milligrams.

The pharmaceutical compositions of the present invention can be embodied as tablets, dragees and capsules, for the oral administration, solutions and suspensions both for oral and parentheral use, and suppositories.

These pharmaceutical compositions can be prepared by using an l,4-benzodiazepine derivative having the above formula (I), at dosage levels of5 to 30 mg, so as to permit the administration of daily total doses of 5 to 90 mg in l to 3 times.

In the pharmaceutical compositions the aforesaid 1,4-benzodiazepine derivatives can be present alone or, alternatively, in combination with other active principles, so as to obtain a composition useful both for the treatment of anxious states and for the treatment: of

functional troubles, the cause of which is at least partially attributable to the same anxious mood. For example, a benzodiazepine derivative could be usefully associated to an antispasmodic drug, e.g.. a compound of the group of the atropine or synthetic analogues, and- /or of the group ofthe papaverine and its synthetic analogues. Lastly the compounds of the present invention can be combined with antianginous drugs, as for example pentaerythritol tetranitrate.

The pharmaceutical compositions of the present invention can be formulated with suitable excipients and diluents, so as to obtain a sustained release, and therefor to extend the effect of the active principles and reduce the number of daily administrations.

The following examples are illustrative of two possible embodiments for the formulation of pharmaceutical compositions containing one of the aforesaid benzodiazepine derivatives, namely 3-N,N-- dimethylcarbamoyloxy-l-methyl-7-chloro-5-phenyl- 1,3-dihydro-2H-l ,4--benzodiazepine-Z-one.

EXAMPLE I 3-N,N-Dimethylcarbamoyloxy-l-methyl-7-chloro-5- phenyl-l ,3-di-hydro-2H- 1 ,4-benzodiazepin-2-one (20 g) is dissolved in 1.6 1 of tetrahydrofurfuryl alcoholpolyethylene glycol ether (Glycofurol); the solution is made up to 2 1 with distilled, pyrogen-free water, then divided in ampules, each containing 2 ml, which are sealed and sterilized by heating at 112C for 20 min. A dosage form containing 20 mg of the active principle and suitable for parenteral administration is thus obtained.

EXAMPLE n I 3-N,N-Dimethylcarbamoyloxyl -methyl-7-chloro-5- phenyl-1,3-dihydro-2H-l,4-benzodiazepin-2-one g) is thoroughly mixed with 600 g of carboxymethylcellulose, 40 g'of talc, 50 g of silica gel (e.g., Gesilite) and l0 g of magnesium stearate; the mixture is sieved through a ZOO-mesh sieve and compressed in tablets weighing 80 mg; these are coated by the usual technique to give sugar-coated tablets, each weighing mg and containing 10 mg of the active principle.

The present invention relates also to the method for the treatment of patients suffering from anxious states according to which a composition containing 5 to 30 mg of a compound having the preceding formula (I) as the active ingredient is administered to the patient.

In a preferred embodiment, the method of the present invention comprises the treatment of the patients suffering from anxiety with a pharmaceutical composition, containing, besides pharmacologically acceptable carriers and excipients, doses of between 5 and 30 mg of 3-N,N-dimethylcarbamoyloxy-l-methyl-7-chloro-5- phenyl-l ,3-dihydro-2H-l ,4-benzodiazepin-2-one.

In the following the results of some pharmacological and clinical tests about some compounds of the preceding formula (I) are summarized in order to permit their outstanding properties and effects to be appreciated.

1. Effects on the spontaneous motility of grouped mice (Dews, Brit. J. Pharmacol. 8, 46 (1953). Each tested compound has been administered, as a suspension in 5 percent carboxymethylcellulose and at a dose of mg/kg per os, to several groups each of five Swiss white mice.

One hour after the administration, the animals have been introduced in the chamber of an actometer having a photoelectrical call detector and their movements have been recorded during 1 hour. In the Table l the percent reductions of motility are reported in comparison with a reference group of mice.

2. Effect on the hypermotility induced by amphetamine on grouped mice (Piala et al. J.Pharmacol.Exptl. Ther. 127, 55, (1959)).

By the same technique as the preceding test, each compound has been tested, at a dose of 10 mg/kg per os, on several groups of mice, which had been previously tested with amphetamine (IO/kg i.p. 2 hours before the administration of the compounds being tested). The percent variation, i.e., either the increase and the decrease, with respect to a control group treated only with amphetamine are reported in Table l.

3. Effect on the behaviour of rats subjected to luminous and acoustical stimuli (reactive motility, open field) (Brimblecome and Green, Nature, 194, 193 (1962)).

A rat is placed within a circular container, having a diameter of 83 cm and surrounded by a wall cm high; the floor of the container is subdivided into zones having a surface area of 250 After a second time for the rat to become familiarized, the rat is subjected to a luminous and acoustical continuous stimulus during about 3 minutes. and the number of zones run through by the rat is counted.

Groups of at least ten rats have been tested without administering any drug; after 24 hours the same rats have been treated with the compounds being tested, at a dose of 25 mg/kg per os.

In the Table 1, the percent variation, i.e., either the increase or the decrease of the number of the zones run through after the administering of the drugs with respect to the number of zones run through in basal conditions are reported.

In the same Table l, the results of the same tests as performed with known 1,4-benzodiazepine compounds, having a structural formula as much as possible close to that of the compounds used in the present invention are shown; these known compounds, which are commonly used in the therapy of anxious states are the following:

Chlordiazepmkide NHbHI Temazepam (EH; 0

0 II Cl The preceding three tests give an indication of the tranquillizing activity, such an indication directly ensuing from the reduced motility of the animals in the tests (1) and (3), whereas in the case of the test (2) an increased hypermotility induced by amphetamine (which is apparently paradoxical), is observed. However, such an effect is known to be characteristic of the benzodiazepines having anxiolytic and tranquillizing activity, as it is also reported in the literature (Taccardi, Arch. ltal.Sci.Farmacol., l2, 3 (1962)); Fleury, Arch.- Sci. 10, 107 (1957)).

Two further pharmacological tests (as hereinafter described at (4) and (5)) have been carried out, in order to evaluate the potential side effects of the compounds being tested. In fact, as it is well known in the related art, the objectionable side effects. which frequently occur in the therapheutical use of tranquillizing drugs containing the known 1,4-benzodiazepine compounds, are exceedingly high sedative action and muscle relaxation liable to induce depression, drowsiness, fatigue and reduced working capability.

4. Potentiation of barbiturate Hypnosis. Groups of ten Swiss white mice have been treated with the tested compounds, at a dose of 10 mg/kg per 0s, and then with 25 mg/kg of nembutal by intraperitoneal route; the duration of the sleep induced by nembutal has been recorded. V

In the Table l, the percent increase of the sleep duration with respect to that induced by the only administration of nembutal is reported.

5. Myorelaxing effect on the mouse by the rotarod test" (Boissier, Therapie, I3, 1074 (I958).

Mice treated with the compounds being tested have been evaluated,as to their capability of keeping their balance for a given time on a rotating rod, in comparison with untreated mice.

In the test, performed on groups of ten mice, the dose (MD inducing the myorelaxing effect (i.e., the falling from the rod) in the 90 percent of the mice has been determined.

Upon considering the Table 1, most of the compounds according to the invention, corresponding to the general formula given in the heading of the same 5 Table, exhibit very interesting pharmacological activity.

In fact:

While the Table 1 does not contemplate all the com pounds corresponding to the indicated meanings of the groups R R and R ofthe formula (I); the pharmacological data therein reported confirm that. as a general 11- from the results f the tests and the rule, all the compounds corresponding to this general novel compounds showapharmacological activity simformula with the related meanings of the aforesaid ilar to that of the therapeutically useful benzodiazegroups are likely to exhibit essentially corresponding pines, but on the contrary their potential sedative acp op ties tion and myorelaxing effects, as indicated by the tests In view of the results and of the indications obtained and (5), a e remarkably reduced. from the pharmacological tests previously referred to,

b. The reduced or absent myorelaxing effects indiand taking it into account the foreseen therapeutical cate, moreover, that the motility inhibiting actions, as use, some further specific pharmacological tests have ShOWn in the tests and are not n q n been carried out and the Applicant is able, for the time of the asthenia and of the ataxia Originating from the being, to furnish the data and the results relating to the muscle relaxation, but only the result ofa tranquillizing compounds No. 6 of the Table 1, namely 3-N,N- activity. dimethylcarbamoyloxy-1-methyl-7-chloro-5-phenyl- It is also to be noticed that the acute toxicity of at ],3-dihyd1- -2H-1,4-benz diaiepin-2-one. least some of the claimed compounds, namely the com- The compound No. 6 has been firstly evaluated acpounds Nos. 1, 2, 4, 5, 6, 9, as tested in mice by oral cording to the tests to 3 at several dose levels and in administration is very low: in fact the LD (lethal dose comparison with Medazepam, as well as with the other causing the death of 50 percent of the animals after the known 1,4-benzodiazepines. stated time) is always greater, after 48 hours, than By these tests further data and information about the 1,000 mg/kg. On the contrary the known benzodiazerelationship between dose and pharmacological effect pines are more toxic, as proved by the data hereinafter have been obtained. The results of these tests are rereported. ported in the following Tables 2, 3 and 4.


ri O N I R2 -0Co or PHARMACOLOGICAL ASSAY OF THE NEW 1,4-BENZODIAZEPINE DERIVATIVES CLAIMED IN THE INVENTION R: I Spontaneous Amphetamine Reactive Barbiturate M-yore- -N motility hypermotillty motility hypnosis laxing (inhibition (variation (variation (increase effect 'ltsl Br R; percent) percent) percent) percent) (MD 00) NH1 51 2 52 +75 I 300 -'NH2 --40 24 +124 250 NHCH3 58 +30 1. +56 400 NHCH3 48 +72 20 +126 300 CH: 40 +56 -60 +32 250 N 6. C113 Same as above 58 +93 -42 +23 4 0 7 NHCH CH CH OH: -5 20 +20 4 lI NHCH CHg0H -26 +100 +17 +3 10 OIIu 31 +16 34 +29 250 12 C 1h Same. as above -45 (l -26 +22 400 1a (In 77 +113 +l.l +2x 250 l I ll l0 1 3.3 I ll -|--.'lll 1 N N (lli Ll umo as above. a -30 8 -35 +29 400 .\lt tlnzvpan1 54 +47 l!) +77 400 l)iazcpa1n 7() +26 +1()h 30 (hlortlinzcpr tltu 4 +51 1 +4 -90 'Imnazcpam -70 til) +81 all TABLE NO. 2

indicated within brackets).

% variation (with respect to the control animals) of the number of counts effected in 60 minutes in the photocell actometer groups of five mice doses mg/kg per os.

Substance Compound No.6 -18(l0) 54(10) 58(l0) 61 87 (5) 95 (5) Medazepam 32(15) 37.6(20) 54(20) 45(5) 45(5) 61(5) Diazepam 67 (5) 66 (5) --70(5) 38(5) 69 (5) -59 (5) Chlordiazepoxide 3 6(10) 4(10) 63(l()) 56(1()) 70(1()) Temazepam -33 (5) 36 (5) 70(5) 96(5) 88 (5) 99 (5) TABLE NO. 3

Hypermotility inducd by amphetamine in grouped mice (the number of mice used is indicated in brackets).

7: Variation (with respect to the control animals) of the number of counts effected in 60 minutes in the photocell actometer groups of five mice doses. mg/kg per 05.

Substance 1 5 0 25 50 100 Compound No.6 +3(10) +4400) +93(10) +150 (5) (5) +64(5) Mcdazepam 0(15) +27 +47(20) +292(5) +245 (5) +330 (5) Diazepam +75(5) +152 (5) +26 (5) +44 (5) +55 (5) l5(5) (hlordiuzepoxide +(10) +20(l0) +51 (10) 24(10) 25(10) 4] (10) Tcmazepam +42(5) +45 (5) +85(5) 25 (5) 49(5) 33(5) TABLE NO 4 The test has been carried out on adult Sprague- Dawley white rats, both male and female and of Comparative effects of the compound No. 6 and 35 grams of welght' of the other known 1.4-benzodiazepines on the reactive motility (open field) in the rat (the number of animals used is indicated within brackets).

71 Variation with Substance Doses respect to the (mg/kg/os) basal values 1 (15) 65,3 Compound No. 6 5 (l5) 9.9

10(15) 26.7 25(15) 42.2 1 (10) 32,1 Medazepam 5 (15) 38.5 10(20) -37,l 25(15) 48,9 Tcmazepam 1 (5) 15.6

The aforesaid further tests were the following:

o. 'l'raclion tcst. relating to thc myorclaxing effect (Boissicr and Simon. 'lherapic. 15, 1 170 (1.960)) in the mouse. The test essentially consists in observing whether or not the animals, suspended by the fore legs to a horizontally taut wire, are capable of raising, up to the height of the wire, the hindlegs. The oral doses (MD 90) of the tested compounds inducing to a myorelaxing effect (i.e., incapacity of raising up to the wire the hindlegs) in the 90 percent of the animals have been determined.

The results of this test plotted in the FIG. 1, are similar to those of the already cited rotarod test, the results of the latter being also plotted in FIG. 2.

7. Effect on avoidance reaction in trained rats.

An automatic programmed conditioning apparatus (made by the firm Basile, of Milan, Italy) has been used, comprising two adjacent compartments, interconnected by an opening and provided with an acoustical stimulator (bell) as well as with an electrical stimulator (electrical connection of a current source to the floor of the compartment).

The rat is left during about 15 minutes inside one compartment, so as to become familiarized; subsequently an acoustical stimulation is applied, for a time of 6 seconds, and after 3 seconds from the beginning thereof, also an electrical stimulation is applied to the animal; when the 6 second time has lapsed, a resting time of 2 seconds is allowed and thereafter the cycle is repeated.

1f the rat enters the second compartment either during the first 3 second time of acoustical stimulation or during the remaining 3 seconds of both acoustical and clcctrical stimulation, the stimuli are automatically stopped. Each displacement from one compartment to the other compartment as well as the time at which such a displacement occurs are recorded by suitable counting and recording means, which are also adapted to distinguish the displacements caused only by the acoustical stimulus (conditioned reflexes) from those caused by the electrical stimulus.

The total number of stimuli, which each rat undergoes for each experimental session of about 20 minutes, is 60. As a consequence, each rat, if well conditioned, can at maximum give 60 conditioned responses.

By means of the above apparatus the rats have been conditioned, by undergoing each day an experimental session of 20 minutes for 15-20 days.

At the end of the conditioning period, the rats have been divided into two groups, namely:

1. those capable of giving 46 to 60 conditioned reactions;

2. those capable to give 16 to 30 conditioned reactions'.

The compound No. 6 and the control compound (temazepam) have been administered by subcutaneous injection to the two groups of rats and, at several times from the administration, the rats have been subjected to the test.

The results are reported in the Table 5. ,160

Upon considering the preceding data, it is evident that a deconditioning marked effect of the tested compounds appears only at the dose of400 mg/kg os for the highly conditioned rats (first group). whereas in the little conditioned rats (second group) at doses of between 10 and 100 tug/kg. an increase of the nunther of the avoidance conditioned reactions is observed. Similar effects are known for other tranquillizers, like diazepam. nitrazepam and chlordiazepoxide (Takaori S. et al., .lap. J.Pharmac. 19, 587, (1969)).

8. Effect on the EECG of the rabbit.

The rabbits have been prepared for the test and the EECG recorded according to the technique described by V. C. Longo (Electroencephalographic Atlas for Pharmacological Research, Elsevier, 1972).

The compound No. 6 and the comparison compound, medazepam, have been administered per os as an aqueous suspension in carboxymethylcellulose at doses ranging between and 30 mg/kg.

After 30 minutes from the administration, a series of EECG has been recorded at intervals of minutes, up to 120 minutes. Every 30 minutes, also the effect of the administered compound on the arousal reaction caused by acoustical, vibro-acoustical and painful stimuli, was determined.

The compound No. 6 caused the duration of the reaction to the various stimuli to be reduced. Such an effect. which was rather moderate at the small dose of 5 mg/kg, is progressively enhanced at the higher doses, and the reaction to the stimuli was sometimes completely absent at doses of -20 mg/kg.

The comparison of the EECG of rats treated with compound No. 6 and with medazepam indicates that the two compounds have a qualitatively similar tranquillizing action, but the former is about three times more active: in fact a dose of 10 mg/kg of compound No. 6 gives place to the same effect caused by a dose of 30 mg/kg of medazepam. Moreover, the effect of the compound No. 6 is already detectable 30 minutes after the administration and is still present after 120 minutes.


Effect on the convulsions induced by strychnine in the mouse.

LD (mg/kg/os) against Strychnine Substance (0.75 mg/kg/Lv.)

Compound No. 6 20 Medazepam 30 Diazepam 20 Dose'stntg/kg) by which the 50'! 0| the mice is |trulcclctl I'rottt the tontc cxtemion of the lttntllegs.


Effect on the convulsions induced by cardiazol in the mouse.

stt (mg/kg/o against Substance cardiazol (40 mg/kg/i.v.)

Compound No. 6 5.8

Medazepam 5 Diazepam 1,55

Chlordiazepoxide 10 Temazepam 6.4

Doses (mg/kg) by which the 50% otthe mice is protected front the tonic extension of the hindlegs.

Besides these tests, aiming to gather information about the claimed products, and particularly about the compound No. 6 in view of the foreseen therapeutical use, extensive toxicological tests have been carried out, namely:

Acute toxicity in mice, rats and guinea-pigs.

Chronic toxicity in rats and dogs.

Teratological tests.

All these tests gave favourable results, thus excluding any objectionable side or toxic effects, which would raise doubts about the foreseen therapeutical use. Of particular interest are the-data relating to the acute toxicity, and from the Table 8 it is clearly evident that the compound No. 6 has a lower toxicity than other drugs of the 1,4-benz0diazepine class; in fact the LD of the compound No. 6 are 1.700 mg/kg (24 hours), 1.200 mg/kg (48 hours) and 970 mg/kg (72 hours) whereas the corresponding values for medazepam are 630, 495 and 476 mg/kg respectively, and diazepam shows an acute toxicity of 720 mg/kg (24 hours).


Acute Toxicity Doses Deaths observed after Substance mg/kg/os LD LD LD mg/kg 48 h mg/kg 72 h mg/kg 250 0/10 0/10 0/10 500 0/10 1/10 3/10 Compound No. 6 750 1/10 1700 (1307-2221) 3/10 1200 (895-1608) 3/10 970 (688-1406) 1000 2/10 4/10 6/11) 2000 7/10 8/10 8/10 250 0/10 0/l0 0/10 500 3/l0 5/l0 6/10 Medazepam 750 6/10 630 (525-756) l0/l0 495 (430-569) 10/10 475 (394-549) 1000 l0/l0 l0/l0 10/10 DL mg/kg 500 l/l0 8/10 l0/I0 Diazcpam 750 67/10 720 (626-828) 8/10 10/10 1000 8H0 10/10 10/10 Another interesting pharmacological characteristic of the compound No. 6, is that the heart contractility is not affected, i.e., depressed.

ln this connection a test has been carried out on awake dogs, according to which, before and after administering the compounds being tested, the left ventricular pressure and its first derivative with respect to time were determined, by means of a cannula, previously inserted by a surgical operation within the said left ventricular cavity (Covell et al., Circulation Research, 19 364 (1966)).

The compound N0. 6 and the chlordiazepoxide have been intravenously injected as a solution in a mixture of water-propylen glycol at the doses of l mg/kg. The measured parameters are indicative of the efficacy of the heart contractility: more particularly, the left ventricular pressure (pvs) is representative of the force generated by the ventricle during the contraction, whereas its derivative (d /dt) is representative of the myocardial velocity of contraction. in the enclosed figures 3 and 4, it can be seen that the ventricular pressure and its derivative are already depressed by 30 percent by a dose of 1 mg/kg of chlordiazepoxide, such a depression becoming more marked and prolonged at a dose of 5 mg/kg of chlordiazepoxide, whereas the same parameters are practically unaffected by l to 5 mg/kg of compound No. 6.

This characteristic of the compound No. 6 is of particular importance in view of a possible use of this substance for the treatment of anxious states in patients suffering from cardiac insufficiency.

Some clinical trials have been carried out with compound No. 6 in a 10 mg oral dosage form and other clinical investigations are in progress.

In some experiments, in order to assess, under controlled conditions, its effectiveness in the treatment of anxiety, the compound was investigated by the double blind method in comparison with one of the previously mentioned known l,4-benzodiazepines, e.g., chlordiazepoxide or temazepam.

For the evaluation of the anxiety symptoms and of their modification by the treatment, the patients to which 3 tablets each containing 10 mg of the active ingredient together with a suitable excipient were administered each day, before and during the treatment, had to answer to a predetermined series of questions concerning their physical and psychical conditions and their attitude toward the external factors and toward the treatment itself.

The questions asked during the interview were derived from the model suggested by W. K. Zung (Rassegna Medica e Culturale, 4, 63 (1,966)). The answers given by the patients were appropriately scored and statistically processed. The results thus obtained can be summarized as follows:

1. The improvement of the anxious symptomatology in the patients treated with compound No. 6 was greater than that obtained either with temazepam and chlordiazepoxide; the difference between compound No. 6 and the comparison drugs was statistically significant.

2. Drowsiness. asthcnia and fatigue, were not obscrved in thc patients treated with compound No. 6, whilst these side effects occurred with the usual incidence in the patients treated with the comparison drugs.

3. A peculiar characteristic of compound No. 6 emerged from this investigation: it is able to improve the mood of the patients, to support a more optimistic attitude andto improve the food appetite; this antidepressant effect differentiates the compound No. 6 from the known l,4-benzodiazepines; the latter exhibiting an exceeding sedation and depression.

The above characteristics of compound No. 6 and the lack of cardiodepressant effect have proved of particular interest; the administration of anti-anxiety drugs, in fact, in some cases, reduces the incidence of anginal attacks in these patients.

In this connection a double blind clinical trial of compound No. 6 in comparison with temazepam, in which three tablets/day containing 10 mg of active compound were orally administered to the patients, has shown a statistically significant superiority of compound No. 6, as measured by the reduced intake of pills of nitroglycerine, a drug giving relief from anginal attacks.

Furthermore the lack of side effects and the improvement of the mood previously observed was evident also in this group of patients receiving the compound No.6.

These clinical trials have completely confirmed the indications given by the pharmacological tests and for this reason also other compounds of the present invention are liable to exhibit like favourable results from the therapeutical point of view.

The pharmaceutical composition of this invention may be administered alone or in combination with another anti-anginal drug.

What is claimed is:

l. A tranquilizing and anti-anxiety pharmaceutical composition including a carrier, and an effective amount of an active ingredient comprising a l,4- benzodiazepin derivative containing a carbamic ester group having the general formula:

wherein R, is selected from the group consisting of hydrogen, and lower alkyls having 1 to 4 carbon atoms, and R and R are, each hydrogen, lower alkyl having from 1 to 4 carbon atoms, cyclohexyl or amino lower alkyl or hydroxy lower alkyl or when R and R are taken together with the attached nitrogen nitrogen atom to form a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, morpholino and piperazino.

2. A pharmaceutical composition according to claim I. wherein said active ingredient is 3-N,N- dimcthylcarbamoyloxy-l-mcthyl-7-chloro-5-phenyl- 1.3-dihydro-2H- l ,4-benzodiazepin-Lone.

3. A pharmaceutical composition according to claim 1, wherein said active ingredient is 3-carbamoyloxy-7- chloro-5-phenyll ,3-dihydro-2H-l ,4-benzodiazepin- 2-one.

9. A pharmaceutical composition according to claim 1, wherein'the dosage of said active ingredient is 10 milligrams. I

10. A method for the treatment of patients suffering from anxious states comprising the administering of a pharmaceutical composition, according to claim 1.

11. A method for the treatment of a patient suffering from anxious states, comprising the administering of a pharmaceutical composition according to claim 2.

12. A method for the treatment of a patient suffering from anginal attacks, comprising the administering of a pharmaceutical composition according to claim 2.

13. A method for the treatment of a patient suffering from anxious states comprising administering a pharmaceutical composition according to claim 1 at a daily dose level of 5 to mg of said active ingredient.

UNITED STATES PATENT OFFICE THICATE G ECTHON Patent 2,8675%; Dated February 18', 1075 Inventor(s) GIORGIO FERRARI and CESARE CASAGRANDE It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

On the first page, beneath the inventors names the name of the Assignee should be inserted as follows:

--Assignee: SIPHAR S,A., Lugano, Switzerland--; and following the Foreign Application Priorty Data, the Swiss Patent No.) reading 126620/70" should read -l2620/70--.

gigncd and gcalcd this twenty-seventh D 3y Of April 19 76 [SEAL] A ties r:

RUTH C. MASON C. MARSHALL DANN Arresting Officer (mnmissinnvr uj'Parenrs and Trademarks

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3255240 *Jun 23, 1965Jun 7, 1966Hoechst AgProcess for preparing beta-hydroxy-alkane-alpha-sulfonic anhydrides and hydrolysis products thereof
US3296249 *Jun 4, 1963Jan 3, 1967American Home Prod5-monocyclic aryl-1, 3-dihydro-2h-1, 4-benzodiazepin-2-ones
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US4190654 *Aug 21, 1978Feb 26, 1980Simes Societa Italiana Medicinali e Sintatici S.p.A.Pharmaceutical composition comprising anxiolytic drugs and beta-adrenergic receptor blocking agents
US4820834 *Mar 16, 1987Apr 11, 1989Merck & Co., Inc.Benzodiazepine analogs
US5030632 *Aug 17, 1990Jul 9, 1991Sandoz Pharm. Corp.Low dose temazepam
US5211954 *Apr 30, 1992May 18, 1993Sandoz Ltd.Low dose temazepam
US5326758 *Mar 17, 1993Jul 5, 1994Sandoz Pharm. Corp.Low dose temazepam
US5629310 *Apr 17, 1995May 13, 1997Sterling; William R.Low dose temazepam
EP0167919A2 *Jun 25, 1985Jan 15, 1986Merck & Co., Inc.Benzodiazepine derivatives and pharmaceutical compositions containing them
U.S. Classification514/221
International ClassificationC07D243/00, C07D243/24, A61K31/55
Cooperative ClassificationC07D243/24, A61K31/55
European ClassificationA61K31/55, C07D243/24